<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03488394</url>
  </required_header>
  <id_info>
    <org_study_id>2017-002430-23</org_study_id>
    <nct_id>NCT03488394</nct_id>
  </id_info>
  <brief_title>Gene Therapy With Modified Autologous Hematopoietic Stem Cells for the Treatment of Patients With Mucopolysaccharidosis Type I, Hurler Variant</brief_title>
  <acronym>TigetT10_MPSIH</acronym>
  <official_title>Phase I/II Study Evaluating Safety and Efficacy of Autologous Hematopoietic Stem and Progenitor Cells Genetically Modified With IDUA Lentiviral Vector Encoding for the Human α-L-iduronidase Gene for the Treatment of Patients Affected by Mucopolysaccharidosis Type I, Hurler Variant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione Telethon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II study evaluating safety and efficacy of autologous hematopoietic stem
      and progenitor cells genetically modified with IDUA lentiviral vector encoding for the human
      α-L-iduronidase gene for the treatment of patients affected by Mucopolysaccharidosis Type I,
      Hurler variant
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pediatric patients with mucopolysaccharidosis type I will be treated with genetically
      modified autologous hematopoietic stem cells collected from mobilized peripheral blood (or
      bone marrow if mobilization is not feasible) and transduced with IDUA lentiviral vector
      encoding for the human α-L-iduronidase gene.

      Patients will be followed for 1 year after gene therapy; after 1 year follow-up they will be
      asked to enroll in a long term study in order to monitor the safety and efficacy of the gene
      therapy treatment for up to 8 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients alive at the end of the trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Achievement of haematological engraftment</measure>
    <time_frame>within day +45 after gene therapy</time_frame>
    <description>First day of neutrophil count more than 500/mm3 and platelets more than 20,000/mm3 on 3 consecutive days (in the absence of transfusions).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of the administration of autologous haematopoietic stem cells transduced with IDUA LV - short term tolerability</measure>
    <time_frame>0-24 hours from injection</time_frame>
    <description>percentage of patients not experiencing short-term adverse events of any grade and systemic reactions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of the administration of autologous haematopoietic stem cells transduced with IDUA LV - absence of Replication Competent Lentivirus</measure>
    <time_frame>0-24 months after gene therapy</time_frame>
    <description>percentage of patients without Replication Competent Lentivirusin the 24 months from injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of the administration of autologous haematopoietic stem cells transduced with IDUA LV - absence of abnormal clonal proliferation</measure>
    <time_frame>0-24 months after gene therapy</time_frame>
    <description>percentage of patients without abnormal clonal proliferation in the 24 months from injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall safety and tolerability (AE)</measure>
    <time_frame>0-24 months after gene therapy</time_frame>
    <description>Number of AEs in the 24 months post injection, summarized by severity and within body system involved.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall safety and tolerability (AE)</measure>
    <time_frame>0-24 months after gene therapy</time_frame>
    <description>Percentage of subjects experiencing AEs in the 24 months post injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall safety and tolerability (SAE)</measure>
    <time_frame>0-24 months after gene therapy</time_frame>
    <description>Number of SAEs in the 24 months post injection, summarized by severity and within body system involved.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall safety and tolerability (SAE)</measure>
    <time_frame>0-24 months after gene therapy</time_frame>
    <description>Percentage of subjects experiencing SAEs in the 24 months post injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IDUA activity in blood</measure>
    <time_frame>1, 2, 3, 6, 9 and 12 months after gene therapy</time_frame>
    <description>IDUA activity measured on peripheral blood dried spot</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-IDUA antibody immune response</measure>
    <time_frame>1, 3, 6 and 12 months after gene therapy</time_frame>
    <description>Presence and titer of anti-IDUA antibody on serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of supraphysiologic IDUA activity in blood</measure>
    <time_frame>1, 2, 3, 6, 9 and 12 months after gene therapy</time_frame>
    <description>IDUA activity measured on peripheral blood dried spot up to supraphysiologic levels as compared with healthy donors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IDUA activity in plasma</measure>
    <time_frame>1, 2, 3, 6, 9 and 12 months after gene therapy</time_frame>
    <description>IDUA activity measured on plasma samples from peripheral blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment of transduced cells at levels above 30%</measure>
    <time_frame>1, 2, 3, 6, 9 and 12 months after gene therapy</time_frame>
    <description>Engraftment will be assessed by vector-specific quantitative PCR on peripheral blood mononuclear cells (PBMC) and/or bone marrow (BM). Adequate engraftment is defined as ≥ 0.30 VCN/genome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization of urinary GAGs</measure>
    <time_frame>1 year after gene therapy</time_frame>
    <description>Proportion of patients achieving normalization of urinary GAG levels (heparansulfate and dermatansulfate) measured by HPLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization of spleen and liver volume</measure>
    <time_frame>1 year after gene therapy</time_frame>
    <description>Proportion of patients achieving spleen and liver volume normal for age, measured by ultrasound</description>
  </secondary_outcome>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Mucopolysaccharidosis IH</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Frozen autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the α-L-iduronidase cDNA, in their final formulation medium.</intervention_name>
    <description>The drug product target dose is more or equal to 8x10^6 CD34+ cells/Kg, with a minimum dose of 4x10^6 CD34+ cells/Kg and a maximum dose of 35x10^6 CD34+ cells/Kg.
The product will be injected intravenously.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent by parent/legal guardian

          -  Sex: Males and Females

          -  Age: ≥ 28 days and ≤ 11 years old

          -  Biochemically and molecularly proven MPS IH

          -  Lansky index &gt;80%

          -  Indication to hematopoietic stem cell transplant

          -  Lack of a non-heterozygous (for mutated IDUA) HLA-matched sibling donor or a ≥7/8 (4
             digits high-resolution typing) HLA-matched cord blood donor with a cellularity ≥5 x
             10^7 Total Nucleated Cells (TNC)/Kg after 1-month search

          -  Adequate cardiac, renal, hepatic and pulmonary functions

        Exclusion Criteria:

          -  Use of other investigational agents within 4 weeks prior to study enrolment (within 6
             weeks if long-acting agents)

          -  Severe, active viral, bacterial or fungal infection at eligibility evaluation

          -  Patients affected by neoplasia or family history of familial cancer syndromes

          -  Cytogenetic alterations associated with high risk of developing hematological
             malignancies

          -  History of uncontrolled seizures

          -  Patients with end-organ damage or any other severe disease which, in the judgment of
             the investigator, would make the patient inappropriate for entry into this study

          -  Positivity for HIV (serology or RNA), and/or HbsAg and/or HBV DNA and/or HCV RNA
             and/or Treponema Pallidum or Mycoplasma active infection

          -  Patients with DQ/IQ &lt;70

          -  Previous allogeneic hematopoietic stem cells transplantation or gene therapy with a
             different product

          -  Contraindications to PeIMP (Product Equivalent to IMP; mobilization and chemotherapy
             agents)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maria Ester Bernardo, MD, PhD</last_name>
    <phone>+390226436329</phone>
    <email>bernardo.mariaester@hsr.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Ester Bernardo, MD, PhD</last_name>
      <phone>+390226436329</phone>
      <email>bernardo.mariaester@hsr.it</email>
    </contact>
    <contact_backup>
      <last_name>Alessandro Aiuti, Prof</last_name>
      <phone>+390226434875</phone>
      <email>aiuti.alessandro@hsr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Alessandro Aiuti, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>MariaEster Bernardo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernhard Gentner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Aldenhoven M, Jones SA, Bonney D, Borrill RE, Coussons M, Mercer J, Bierings MB, Versluys B, van Hasselt PM, Wijburg FA, van der Ploeg AT, Wynn RF, Boelens JJ. Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines. Biol Blood Marrow Transplant. 2015 Jun;21(6):1106-9. doi: 10.1016/j.bbmt.2015.02.011. Epub 2015 Feb 20.</citation>
    <PMID>25708213</PMID>
  </reference>
  <reference>
    <citation>Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, Baldoli C, Martino S, Calabria A, Canale S, Benedicenti F, Vallanti G, Biasco L, Leo S, Kabbara N, Zanetti G, Rizzo WB, Mehta NA, Cicalese MP, Casiraghi M, Boelens JJ, Del Carro U, Dow DJ, Schmidt M, Assanelli A, Neduva V, Di Serio C, Stupka E, Gardner J, von Kalle C, Bordignon C, Ciceri F, Rovelli A, Roncarolo MG, Aiuti A, Sessa M, Naldini L. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013 Aug 23;341(6148):1233158. doi: 10.1126/science.1233158. Epub 2013 Jul 11.</citation>
    <PMID>23845948</PMID>
  </reference>
  <reference>
    <citation>Capotondo A, Milazzo R, Politi LS, Quattrini A, Palini A, Plati T, Merella S, Nonis A, di Serio C, Montini E, Naldini L, Biffi A. Brain conditioning is instrumental for successful microglia reconstitution following hematopoietic stem cell transplantation. Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15018-23. doi: 10.1073/pnas.1205858109. Epub 2012 Aug 23.</citation>
    <PMID>22923692</PMID>
  </reference>
  <reference>
    <citation>Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, Vidaud M, Abel U, Dal-Cortivo L, Caccavelli L, Mahlaoui N, Kiermer V, Mittelstaedt D, Bellesme C, Lahlou N, Lefrère F, Blanche S, Audit M, Payen E, Leboulch P, l'Homme B, Bougnères P, Von Kalle C, Fischer A, Cavazzana-Calvo M, Aubourg P. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 2009 Nov 6;326(5954):818-23. doi: 10.1126/science.1171242.</citation>
    <PMID>19892975</PMID>
  </reference>
  <reference>
    <citation>Hong KT, Kang HJ, Kim NH, Kim MS, Lee JW, Kim H, Park KD, Shin HY, Ahn HS. Successful mobilization using a combination of plerixafor and G-CSF in pediatric patients who failed previous chemomobilization with G-CSF alone and possible complications of the treatment. J Hematol Oncol. 2012 Mar 30;5:14. doi: 10.1186/1756-8722-5-14.</citation>
    <PMID>22458355</PMID>
  </reference>
  <reference>
    <citation>Martin HR, Poe MD, Provenzale JM, Kurtzberg J, Mendizabal A, Escolar ML. Neurodevelopmental outcomes of umbilical cord blood transplantation in metachromatic leukodystrophy. Biol Blood Marrow Transplant. 2013 Apr;19(4):616-24. doi: 10.1016/j.bbmt.2013.01.010. Epub 2013 Jan 22.</citation>
    <PMID>23348427</PMID>
  </reference>
  <reference>
    <citation>Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C, Sergi Sergi L, Benedicenti F, Ambrosi A, Di Serio C, Doglioni C, von Kalle C, Naldini L. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol. 2006 Jun;24(6):687-96. Epub 2006 May 28.</citation>
    <PMID>16732270</PMID>
  </reference>
  <reference>
    <citation>Muenzer J, Fisher A. Advances in the treatment of mucopolysaccharidosis type I. N Engl J Med. 2004 May 6;350(19):1932-4.</citation>
    <PMID>15128891</PMID>
  </reference>
  <reference>
    <citation>Shapiro EG, Nestrasil I, Rudser K, Delaney K, Kovac V, Ahmed A, Yund B, Orchard PJ, Eisengart J, Niklason GR, Raiman J, Mamak E, Cowan MJ, Bailey-Olson M, Harmatz P, Shankar SP, Cagle S, Ali N, Steiner RD, Wozniak J, Lim KO, Whitley CB. Neurocognition across the spectrum of mucopolysaccharidosis type I: Age, severity, and treatment. Mol Genet Metab. 2015 Sep-Oct;116(1-2):61-8. doi: 10.1016/j.ymgme.2015.06.002. Epub 2015 Jun 17.</citation>
    <PMID>26095521</PMID>
  </reference>
  <reference>
    <citation>Visigalli I, Delai S, Politi LS, Di Domenico C, Cerri F, Mrak E, D'Isa R, Ungaro D, Stok M, Sanvito F, Mariani E, Staszewsky L, Godi C, Russo I, Cecere F, Del Carro U, Rubinacci A, Brambilla R, Quattrini A, Di Natale P, Ponder K, Naldini L, Biffi A. Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood. 2010 Dec 9;116(24):5130-9. doi: 10.1182/blood-2010-04-278234. Epub 2010 Sep 16.</citation>
    <PMID>20847202</PMID>
  </reference>
  <reference>
    <citation>Weisstein JS, Delgado E, Steinbach LS, Hart K, Packman S. Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation. J Pediatr Orthop. 2004 Jan-Feb;24(1):97-101.</citation>
    <PMID>14676543</PMID>
  </reference>
  <reference>
    <citation>Wraith JE, Rogers JG, Danks DM. The mucopolysaccharidoses. Aust Paediatr J. 1987 Dec;23(6):329-34.</citation>
    <PMID>3124802</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2018</study_first_submitted>
  <study_first_submitted_qc>March 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2018</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Alessandro Aiuti</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Mucopolysaccharidosis IH</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>Transplantation, Autologous</keyword>
  <keyword>Lentiviral vector</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis I</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

